Dr. McCollum on Drug Sequences for Patients With CRC

A. David McCollum, MD
Published: Friday, Nov 17, 2017



A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses drug sequences for patients with colorectal cancer (CRC).

Patients with CRC are generally treated with a biologic drug in combination with chemotherapy. Over time, the intensity of the chemotherapy is modified or lightened to try to maintain benefit for as long as possible.

There is still debate about which maintenance therapy is best for frontline treatment, as well as what constitutes as enough progression for a patient to need second-line therapy, says McCollum.
SELECTED
LANGUAGE


A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses drug sequences for patients with colorectal cancer (CRC).

Patients with CRC are generally treated with a biologic drug in combination with chemotherapy. Over time, the intensity of the chemotherapy is modified or lightened to try to maintain benefit for as long as possible.

There is still debate about which maintenance therapy is best for frontline treatment, as well as what constitutes as enough progression for a patient to need second-line therapy, says McCollum.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x